✎ IP Commission’s conference strengthens India’s biosimilar ecosystem through innovation, safety standards, and global competitiveness under SHAKTI Vision.
Relevance for Banking, SSC & RBI Grade B exams: Security
The Indian Pharmacopoeia Commission (IPC) organized a two-day national conference on “Quality and Safety of Biosimilars: Strengthening India’s BioPharma SHAKTI Vision” in Bengaluru, aligning with the government’s SHAKTI initiative to boost India’s biopharmaceutical ecosystem through innovation, self-reliance, quality, and global competitiveness. The event, held in collaboration with the Indian Drug Manufacturers’ Association (IDMA), C-CAMP, and BIRAC, brought together regulators, industry leaders, academia, and researchers to discuss critical scientific and regulatory challenges in biosimilars, including pharmacopoeial standards, analytical characterization, immunogenicity, and evolving regulatory expectations. A key highlight was the launch of the Indian Pharmacopoeia Reference Standard (IPRS) for Enoxaparin Sodium for bioassays, which will ensure accurate and comparable evaluation of its biological activity, reinforcing India’s indigenous drug quality infrastructure and contributing to the *Atmanirbhar Bharat* vision.
For banking, SSC, and RBI Grade B aspirants, this development underscores the growing importance of India’s pharmaceutical and biotechnology sectors in national and global supply chains, directly impacting financial policies, trade, and regulatory frameworks. The SHAKTI vision’s focus on quality and innovation in biosimilars reflects India’s push for self-sufficiency in critical healthcare segments, which is crucial for exam contexts like economic surveys, financial inclusion, and healthcare sector reforms. Additionally, the emphasis on regulatory standards and collaborations highlights the need for robust governance and compliance mechanisms—key areas tested in these examinations.
Source: PIB (Press Information Bureau)
Generated by AanyaAi for educational purpose.
1 comment on “IPC National Conference on Biosimilar Safety & Quality for Banking Exams 2026”